R&D | November 14, 2025
UK MHRA finds gut microbiome research unreliable across labs
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
The launch coincides with IBS Awareness Month in April
A brand from Opella will be part of the official NASA astronaut formulary
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
These distinct gut microbial signatures can be used to predict the risk of developing long Covid and diagnose long Covid in patients with persistent symptoms after the acute infection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
